Free Trial

Basilea Pharmaceutica (OTCMKTS:BPMUF) Hits New 52-Week Low - Time to Sell?

Basilea Pharmaceutica logo with Medical background

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $51.00 and last traded at $51.00, with a volume of 10 shares. The stock had previously closed at $54.00.

Basilea Pharmaceutica Price Performance

The business has a 50 day moving average of $53.04 and a 200 day moving average of $52.84. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10.

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

Featured Articles

Should You Invest $1,000 in Basilea Pharmaceutica Right Now?

Before you consider Basilea Pharmaceutica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.

While Basilea Pharmaceutica currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

7 Cybersecurity Stocks Outperforming the Market Right Now
Markets in Rally Mode: Will Earnings Keep It Going?
3 Tech Stocks to Buy Now—And 3 You’ll Regret Keeping

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines